Donor-derived anti-CD19 CAR-T cells
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for Donor-derived anti-CD19 CAR-T cells, covering 2026-04-08 to 2026-04-08. Get the full timeline:
Most recent: Clinical Trial Update: Administration of Anti-CD19-chimeric-antigen-receptor-transduced T Cells From the Original Transplant Donor to Patients With Recurrent or Persistent B-cell Malignancies After Allogeneic Stem Cell Transplantation [Phase 1]